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Abstract: The rules of governance are changing. They are necessarily becoming more stringent as interventions offered to 
treat conditions carry unpredictable side effects, often associated with novel therapeutic vectors. The clinical relevance of 
this relates to the obligations of those involved in research, to ensure the best protection for subjects whilst encouraging 
the development of the field. Existing evidence supports the concept of e-Governance both in operational health research 
and more broadly in the strategic domain of policy formation. Building on the impact of the UK Comprehensive Research 
Network and recent EU Directives, it is now possible to focus on the issues of regulation for cell therapies in 
musculoskeletal science through the development of the Advanced Therapeutic Medicinal Products (ATMP) category of 
research products. This article reviews the framework that has borne this and the need for more detailed Virtual Research 
Integration and Collaboration (VRIC) systems to ensure regulatory compliance. Technology research and development 
plans must develop in close association between tissue engineering and treating clinicians. The scope of this strategy 
relates to the handling of human tissues the transport and storage of specimens in accordance with current EU directives 
and the Human Tissue Authority (HTA) regulations. 
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‘The things that will destroy us are; 
politics without principles 
pleasure without conscience 
wealth without work 
knowledge without wisdom 
business without morality 
science without humanity 
and worship without sacrifice’ 
- MK Gandhi [1] 
  Governance has been aligned with humanity since the 
dawn of conscience, but with the information revolution has 
crystallised this into a new form. Governance is defined as 
‘the persons who make up a body for the purpose of 
administering something’ [2]. 
  e-Governance, short for electronic governance [3], uses 
new information and government technologies to make 
governance ‘more efficient and more effective’ [4]. 
Advancement of Information and Communications 
Technology (ICT) and the implementation of these 
information services within the public sector increases and 
improves the operational service provision. This embraces 
all stakeholders; the government, its citizens, and businesses 
[5]. E-Governance may thus improve service provision by 
improving communication between the government and its 
stakeholders, leading to a more inclusive and holistic modus 
operandum [6]. 
  In economic theory, such government intervention, seen 
as correcting ‘market failure’ of a public good or service, is 
generally the nature of electronic public service provision, 
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and breaks down communication barriers between 
stakeholders and generates economies of scale [7]. Fig. (1) 
illustrates the interactions between stakeholders in e-
Governance. 
 
Fig. (1). Interactions between groups in e-governance. Adapted 
after M Bucker [8]. 
  So how prevalent now is e-Governance in the UK? The 
provision of twenty basic public services online (such as tax, 
public libraries and car registration) across the European 
Union (EU) and the total online public service provision 
averaged 58% in 2007 (compared to 50% in 2006). The UK 
has approximately 90% of the designated public services 
available online, whilst Austria leads with 100% provision 
[9]. So with such an established approach, what role cans e-
Governance plays in health research? 
  The National Institute for Health Research Clinical 
Research Network (NIHR CRN) aims to improve healthcare 
in the UK by increasing the efficiency and speed of the 
translational research process, through providing an 
electronic infrastructure for clinical research. This 
infrastructure supports ‘Patient and Public Involvement’ in 
healthcare (PPI) to encourage more recruits to join clinical 
trials, and to improve the coordination of the NHS and 
sponsors (non-governmental organisations) and the private 
sector [10]. Fig. (2) shows how the broader role of the NIHR 
as outlined by the Department of Health in their “Best 
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  NIHR CRN was established in response to the EU 
Clinical Trials Directive (CTD 2001/20) which was 
incorporated into British legislation in the Medicines for 
Human Use (Clinical Trials) Regulations 2004 [12]. This 
legislation imposed more bureaucracy in clinical trials with 
the new regulations and conversely it was thought to slow 
down translational research [13]. In pharmaceutical clinical 
trials, 70% of trials in phase 2 of testing end because of 
toxicity or lack of efficacy, and only 20% of drugs entering 
clinical trials will ever reach the marketplace [14]. Thus it is 
important that if a trial is to be carried out with only one in 
five of drugs tested actually becoming licensed, the subjects 
being tested should be done so under the best possible 
condition. However there have been some reports that the 
implementation of the clinical trials directive has slowed and 
even halted the initiation of clinical research [15]. The 
application of e-Governance was thus considered a vehicle to 
overcome these hurdles in the creation of the NIHR 
comprehensive research network (CRN). 
  Musculoskeletal medicine is exploiting this infrastructure 
through an initiative with the NIHR CRN in a model of e-
Governance. Facilitated by the Arthritis Research Campaign 
(ARC) targeted research initiatives in seven topic areas with 
non-governmental organisations, researchers and industry 
authorities, led to a programme of clinical trials which will 
provide a well-defined route for translational research within 
musculoskeletal medicine [16]. 
THE RESEARCH GOVERNANCE LEGAL 
FRAMEWORK 
  The comprehensive clinical research network (CCRN), 
launched in 2007 as part of the government’s research and 
development strategy, ‘best research for best health’, is one 
of 8 clinical research networks (CRNs) in England forming 
the infrastructure of the National Institute for Health 
Research (NIHR). This virtual national research framework 
is aimed at managing and maintaining the research, research 
staff and infrastructure of the NHS. 
  The first ‘CRN’ to materialise was the national cancer 
research network (NCRN), in 2001. Since then, seven other 
CRNs developed, guided by the UK clinical research 
network coordinating centre (UKCRN CC). These CRNs 
eliminate geographical barriers within the NHS, allowing 
patients and healthcare professionals from all parts of the 
country to participate in and benefit from clinical research 
[17]. The comprehensive clinical research networks (CCRN) 
were developed to extend the current CRN infrastructure to 
cover all healthcare topics, facilitating access to NHS 
patients and research facilities for research within CRNs 
[18]. It provides a framework, allowing allocation and 
management of funding for NHS service support, including 
clinicians’ time, and streamlines the research management 
process to reduce the burden on researchers. The CCRN is 
subdivided into 25 comprehensive local research networks 
(CLRNs), with ‘resident’ populations of about 2 million. 
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  The CCRN forms part of the NIHR portfolio, an 
information database that ensures all CRN studies are 
registered, enabling open national competition and peer 
review. This allows the CCRN, via appropriate CLRNs to 
provide research management and support services [19]. 
  Information about clinical research can therefore be 
centralised, making it easier to regulate standards and ensure 
Good Clinical Practice (GCP). This was defined in the 2001 
EU directive as ‘a set of internationally recognised ethical 
and scientific quality requirements which must be observed 
for designing, constructing, recording and reporting clinical 
trials that require the participation of human subjects’ [20]. 
In the UK, a section of the Medicines and Healthcare 
products Regulation Agency (MHRA), the GCP 
inspectorate, is responsible for making sure that clinical 
trials comply with GCP. The GCP directive requires an 
approval to be obtained from an Independent Ethics 
Committee (IEC) before a trial starts. Study design and 
protocol, investigators, staff and facility quality, consent 
process, risk assessment, indemnity and payments all require 
appraisal. Similar to the NIHR portfolio, the EudraCT 
database was previously set up as part of the GCP directive 
to share information between member states regarding trial 
submission dates, ethical approvals and GCP inspections. 
Whereas the NIHR portfolio regulates clinical trial standards 
in the UK, EudraCT monitors GCP compliance across all of 
Europe. This facilitates implementation of directives as 
information regarding current clinical trials and protocols 
through one central database. 
  Greater use of e-Governance has been adopted by several 
European Union Governments, including the UK [21, 22]. 
Electronic resources, such as the internet can be used to 
improve both the administration and consumer (citizen) 
access to government schemes, resources and services. E-
Governance therefore allows consumers to interact with 
various departments online. Services are delivered in a 
manner that best suits them and with government citizen 
interaction streamlining, information can be forwarded to 
several departments, increasing the efficiency of their 
interaction [3]. 
  E-Governance for health research administration 
therefore allows for the support and coordination of 
otherwise diffuse research projects [23], it simplifies 
procedures, for initiating and maintaining a research project, 
such as funding application and patient recruitment, 
removing many of the barriers to carrying out research of a 
high quality. This streamlining of processes should ideally 
place no research project at a disadvantage, regardless of 
location when accessing resources. Administered by the 
Comprehensive Clinical Research Network (CCRN) and its 
allied specialist research networks [23], the operational 
delivery of the Government’s “Best Research for Best 
Health” [24] strategy links trial coordinators to the various 
providers of resources with this framework. 
MUSCULOSKELETAL OPERATIONAL IMPLEMEN-
TATION STRATEGIES 
  It has been argued that the directive, by enforcing stricter 
regulation has erected a barrier to certain types of research 
and in some cases may prohibit entirely some trials that 
could have been carried out pre-directive [25]. The increased 
bureaucratic burden accompanying the directive has slowed 
both the workflow of the sponsor and the passage of the trial 
through the IEC stage. This increased time burden during the 
preparatory stages stretches the already limited resources of 
the sponsor. In conjunction with increased insurance costs 
consequent upon the directive, this has meant that the 
number of trials initiated has fallen. 
  This may have both a direct and indirect detrimental 
effect on patient health since trial drugs often improve the 
quality of life of participants. Drugs released as a result of 
such trials are ultimately added to the arsenal of anti-cancer 
therapies available for the treatment of future patients. Many 
studies that previously would have been carried out 
independent of academic grants now require additional 
funding, by ‘Big Pharma’ resources. It is arguable that the 
UKCRN and the EU directives work in almost a counter 
balancing manner. The end result should be though that 
research can proceed, whilst patient protection and reliable 
data procurement are ensured. 
THE RELEVANCE TO SURGICAL INTERVENTIONS 
  Trials of surgical procedures would not normally be 
considered trials of medicinal products and so are not 
governed by the EU directive but are required to adhere to 
the Department of Health (DH) Research Governance 
Framework for Health and Social Care [26]. This is to 
“ensure that the public can have confidence in, and benefit 
from, quality research in health and social care”. It is the 
responsibility of those carrying out the study to ensure that 
the guidelines are followed – in order that good clinical 
practice may be achieved. This emphasizes “The dignity, 
rights, safety and well-being of participants must be the 
primary consideration in any research study”. 
  Trials that have separate analysis of treatment effects in 
children are important, due to their differing physiologies 
[27] and an increase in trials in children may result to reflect 
this. It is likely that adult Stem Cell work will need to be 
satisfactorily completed first. 
  The Council of Europe defined e-Governance as “a set of 
technology-mediated processes that are changing both the 
delivery of public services and the broader interactions 
between citizens and government” [28]. As the “delivery” of 
e-Governance has begun to modernise and streamline diverse 
processes such as researcher-institution interactions. Patient 
information availability for both clinicians and patients [29] 
tools has developed to share trial information between 
clinicians, such as the Orthopaedic Research Base Service 
(ORBS) and the Virtual Research Integration and 
Collaboration Network (VRIC) (Fig. 3). 
  The “Best Research for Best Health” strategy [30], 
specifically strengthens research processes and 
collaborations between NHS, the university sector and 
stakeholders so to facilitate the research of non-NHS 
clinicians, who have a “direct bearing on the quality of care” 
of patients under the NHS across different NHS Trusts. The 
“Research Passport” allows investigators to collaborate 
across jurisdictions to manage human resources including 
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  Further streamlining of the process employs an online 
application system to get NHS permission for clinical trials 
that fall within the NIHR Clinical Research Network 
Portfolio within the UK. The IRAS (Integrated Research 
Application System) provides a single integrated entry point 
for approval for research for a variety of governing bodies 
[29]; 
•  Administration of Radioactive Substances Advisory 
Committee (ARSAC) 
•  Gene Therapy Advisory Committee (GTAC) 
•  Medicines and Healthcare products Regulatory 
Agency (MHRA) 
•  Ministry of Justice 
•  NHS / HSC R&D offices (applicable to all trials) 
•  NRES/ NHS / HSC Research Ethics Committees 
(applicable to all trials) 
•  Patient Information Advisory Group (PIAG) 
  This single access point decreases the time necessary for 
the Investigator and governing body alike. The European 
Union Clinical Trials Directive (EUCTD) makes the process 
“clear and transparent” [33, 34] and dictates how the 
progress of the research should be monitored, and how 
practice should be assessed since 2001 [35]. 
  With the National Institute for Health Research (NIHR) 
Comprehensive Clinical Research Network (CCRN) [36]. 
Intending to provide a world-wide information base about 
clinical trials pertaining to any disease and hence display 
clinical need within the NHS [36], the role of each individual 
involved in the study is now better defined, so that each may 
know his exact function in terms of the trial, and so people 
can be trained specifically. 
  If there was no waiver of informed consent, then it was 
not possible to recruit patients into clinical trials in 
emergency circumstances, such as in intensive care units, but 
the directive endorses surrogate consent by a “legal 
representative”; defined by that country’s specific laws to a 
family member [37]. In spite of these attempts to improve 
the process, one study also showed that although the number 
of studies fell by 63% the trial costs actually increased by 
85% with insurance doubling from 70 million to 140 million 
Euros [38]. 
REGULATION OF CELL THERAPIES  – A WHOLE 
NEW CLASSIFICATION 
  Many issues must be taken into account. Stem cells 
themselves remain part of an ethical debate. Adult stems 
cells (Mesenchymal Stem Cells – MSCs) are widely allowed 
in research as they equate to, a bone marrow transfusion 
[39]. Stem cells from already aborted foetuses are more 
controversial but not as controversial as human embryonic 
stem cells (hES) taken from early embryos in the blastocyst 
stage of development [39]. 
  The UK first formulated a law that acted to govern the 
use of human embryos for stem cell research and the 
European Science Foundation now collates the various 
stances of the governments of different countries on this 
topic [40]. In most cases the source of hES cells has been 
spare embryos from ‘In Vitro Fertilisation (IVF) treatment 
and Article 18 of the European Convention on Human 
Rights and Biomedicine prohibits the creation of all embryos 
specifically for research purposes [40]. 
  The EU Tissues and Cells Directive for regulation of cell 
based therapies governs the use of tissues in research and 
clinical use, including safety and quality of cellular 
“donation, procurement, testing, processing, preservation, 
storage and distribution” [41]. The Directive considers stem 
cell handling, with regard to the stem cell processing when 
the cells are exposed to the environment provided by a 
laminar air flow cabinet or a clean room facility [41]. These 
regulations help to govern cell usage in a way that makes the 
procedure safer, more cost and time efficient, and with a 
higher quality standard of practice. 
  A more recent directive from the European Union is the EU 
Tissue Directive 2004. This set clear guidelines, standardising 
stem cell protocols throughout Europe [42]. With regards the 
donated and processed tissue, it must be tested for infectious 
diseases and it must be characterised. Patients with allogenic 
tissue must undergo a thorough medical examination. It may be 
necessary for the subject to undergo a psychiatric interview to 
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assess whether or not they are mentally fit to undergo a 
procedure which uses embryonically derived cells. This EU 
Tissue Directive has been criticised for its lack of clear legal 
guidelines, leading to widespread discrepancies throughout 
Europe with regards the laws they adhere to, in terms of their 
stem cell research [43]. When designing a study for stem cell 
treatment, such as to evaluate their effectiveness in fracture 
healing as in the case of the PACINO study, all these 
regulations must be met for the characterised stem cell type 
(bone marrow derived mesenchymal stem cells – BMD MSCs). 
  Again, manifest through the principle of subsidiarity; the 
Human Tissue Act 2004 regulates the use of human tissue being 
used in research. The key components of this law relating to cell 
therapy research are that the researcher must be licensed to carry 
out these activities and that donor consent must be obtained for 
the research [44]. As of 2004, a somatic cell therapy being used 
in research was classified as an investigational medicinal 
product. These cells are part of research involving ‘Advance 
Therapy Medicinal Products’ (ATMPs) – regenerative cell 
therapy products. Obtaining the cells and using them in research 
must therefore be licensed by the Human Tissue Authority [45]. 
  It is both a legal and statutory requirement that cell-based 
research adhere to these regulations before the planning of a 
clinical trial. Under the EU Tissue and Cell Directives Quality 
and Safety (Q&S) regulations 2007 (implemented as the Human 
Tissue Regulations 2007) and enforced by the Human Tissue 
Authority (HTA), cell-based treatment studies on patients are 
additionally required to take place in institutions with HTA 
licensure in the procurement, testing, processing, import/export, 
and distribution of human tissue. The institution is required to 
meet the standards according to ‘Good Manufacturing Practice’ 
and three directions detailed by the HTA: 001/2006, 002/2007 
and 004/2007 [46]. 
  According to the Medicine and Healthcare Regulatory 
Agency (MHRA) and HTA, the use of stem cell treatment in 
this MRC funded double blinded randomised controlled trial of 
fracture healing using MSCs falls into the definition as an 
advanced therapy medicinal products/tissue engineering 
(ATMP). Non-routine applications of ATMPs on individual 
patients in hospital in accordance with a prescription are even 
exempted from ATMP regulations. However, exemption of 
such regulation must continue to follow the HTA Q&S 
regulations [47]. 
EARLY CLINICAL STUDIES AND THEIR 
REGULATION 
 Musculoskeletal stem cell work involves adult 
mesenchymal stem cells (MSCs) that are blood, bone marrow 
[48] and dermally derived [49], though this distinction may not 
yet be fully appreciated beyond the biomedical community [50]. 
Stem cells remain controversial since they are unpredictable 
with respect to their differentiation and amplification. 
Pluripotent embryonic stem cells also represent a risk of 
teratoma formation in contrast to adult stem cells, which lack 
distinct teratogenic potential but remain multipotent [51]. 
  With the EU directives and subsequent National implemen-
tation protecting patient welfare, this may restrict the application 
of MSCs in clinical trials, as they may pose a risk to the patient, 
similar to the issues surrounding novel gene therapy [51, 52]. It 
is therefore vital to demonstrate their safety as well as efficacy, 
classically called phase I and phase II trials. 
  The EU Tissues and Cells Directive [53-55] were brought 
into UK law in 2007. It delegated the Human Tissue Authority 
(HTA) to regulate stem cell lines grown outside the human 
body for human application [56].  There must be compliance 
with the established regulations for handling of injectable 
biological agents. The same is true of the operational procedures 
derived from this strategic scientific approach. 
  The process of modification of the initial substrate, either 
cells or a biologically active agent must be a clearly defined by 
the ‘end to end’ regulated governing process, to ensure the 
appropriate compliance with MHRA regulations in the UK, 
European Medicines Agency (EMA) regulations across Europe 
and the Food and Drugs Administration (FDA) regulations in 
the USA. This requires Good Laboratory Practice (GLP), Good 
Manufacturing Practice (GMP), Good Clinical Practice (GCP) 
compliance  etc, at the various stages of this Translational 
Research (TR) pipeline. 
  Quality Assurance (QA) depends on the Standard Operating 
Procedures (SOPs), often protecting Intellectual Property (IP), 
since the organisations have invested in developing and refining 
these processes. They detail the agents and timings for filtering 
and expanding of cell colonies, maintaining differentiation into 
specific cell types or de-differentiation to maintain ‘stemness’ 
with evidence of induction of MSC differentiation for potential 
clinical applications [57]. 
  Any biological agent should be monitored, including long-
term surveillance. This has been promoted as a philosophy 
within the cartilage community represented by the International 
Cartilage Repair Society (ICRS) [58, 59] and for a registered 
UKCRN clinical trial, if adverse events do occur downstream, 
the association with this trials can be identified [60]. The 
development of a cell based registry is still awaited. As with 
arthroplasty, this intervention registry should allow for non-
repudiable anonymised data to reconcile with cancer registries 
in order to either detect early association or ultimately allay 
fears of inappropriate cell transformation which underlies any 
type of biological intervention. 
CONCLUSIONS 
  What might first appear to be a regulatory barrier is simply a 
series of highly complex filters providing checks and balances 
to ensure risk mitigation for trial subjects. Certain ‘entry level’ 
criteria are therefore essential before considering embarking on 
even on collaboration with such work. Such organisation’s 
governance processes should consider who the stakeholders are 
in this process and what specimens need to be monitored. When 
records need to be kept and reviewed and where specimens can 
be held and the standards of facilities required. It is vital to 
understand why such processes are to be monitored and 
reported and how this will be delivered locally. 
  Anyone involved in either the clinical collection of 
specimens or their handling, both in transit and in the laboratory 
in the organisation, needs to be aware of this and those directly 
involved should be GCP certified. 
  All specimens which are collected from human subjects 
either for research in a non-GLP facility or processed in the 
GLP tissue fabrication facility need to be identifiable, though 
anonymised before transfer for basic science work unless it is 
specifically part of the protocol, for example in trials where 
GMP facilities are to be used and cells replanted. e-Governance  The Open Orthopaedics Journal, 2011, Volume 5    281 
  Records need to be held by each institution, and reconciled 
with each other in order to ensure reliable and consistent 
tracking of tissue specimens. It is not essential that the records 
are completed immediately, due to the more pressing matters 
such as ensuring preservation of the specimens, but certainly the 
records should be updated within a working week of any tissue 
transfers. Modern bar-coding can ease most of these 
administrative tracking duties. 
  These are then available for review by the licence holders, 
or their designated individuals. Such records are a legal 
requirement for the organisations, and as such, should be 
available for inspection by authorities such as the medicines and 
Healthcare products regulatory agency (MHRA) and the 
Human Tissue Authority (HTA). These organisations notify in 
advance in writing of any inspections, but best practice should 
ensure that records are kept up-to-date. 
  Part of this process is the development of the concept of 
corporate governance. This involves integration of components 
of research, clinical and information governance. These policies 
need to be integrated, in the same way as with research 
pipelines; main areas of good laboratory practice (GLP), good 
clinical practice (GCP) and good manufacturing practice (GMP) 
interrelate. Other areas of regulation that does not impact 
directly here, are good pharmacovigilence practice (GPvP) and 
good delivery practice (GDP) but are dealt with by the 
pharmacy. 
  By linking adequate facilities (fit for purpose) directly, so 
that specimens are handled and logged in and out these 
facilities, traffic between operating theatres and the Institutional 
laboratories is monitored. Once specimens are handled within 
the laboratory, it depends whether specimens need to be handled 
in accordance with good laboratory practice (GLP) processes or 
whether the experiments on cells do not require this. It is 
therefore necessary if the specimens are to be handled in 
accordance with GCP and GLP requirements that there are 
tissue transfer agreements in place for any such trials. 
  In order to facilitate integration, it is sensible to employ a 
single system for the tracking of tissue specimens that can link 
to the trials registry as well as in the virtual research integration 
and collaboration environment (VRIC). This should cover the 
interface with the clinical services and thus the jurisdiction of 
the clinical HTA licence holder. Inclusion of the GLP and non-
GLP facilities remains under the jurisdiction of the research 
HTA licence holder. Such processes are likely to be reformed in 
future, as recommended by the Academy of Medical Sciences 
report [61] which proposes ‘A new pathway for the regulation 
and governance of health research’. The only certainty is 
change, and administrations need to be able to accommodate 
this. E-Governance is likely to be the most effective method, but 
needs a different approach that is better metered to the perceived 
risks and is imposed by government per se, rather self 
governing. 
  The adoption of a database is only part of the solution for 
the operational delivery of this strategic e-Governance policy. 
Staffs need training to accurately record specimens in the 
system and also monitor the transport across sites. This should 
be as straightforward as possible, but fully compliant with all 
regulation to be reviewed at least biannually. 
  It is only when the entire process of ‘top-down’ and 
‘bottom-up’ management of such trials is reconciled that society 
will be able to reflect on whether these reforms have achieved 
their original goal of improving safety and efficacy of such trials 
for these advanced therapeutic products and society can 
comfortably move forward with the clear conscience that 
regulation is in place but the necessary burden does not stifle 
innovation. 
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